CLAIMS

1. Use of a polypeptide that binds F-protein of hRSV with a K_D of $5x10^{-10}$ M or less, that neutralizes hRSV with an IC90 of 90 ng/mL or less, and that comprises, consists essentially of, or consists of three anti-hRSV immunoglobulin single variable domains, in the preparation of a medicament for use in the treatment of RSV infection in a young child, wherein the polypeptide is to be administered to the child suffering RSV infection by inhalation at a deposited dose of 0.020-0.040 mg/kg daily.

2. Use according to claim 1, wherein an inhaled dose is 0.20-0.40 mg/kg daily.

3. Use according to any one of claims 1 to 2, wherein a nominal dose is 1.00-2.00 mg/kg daily.

4. Use according to any one of claims 1 to 3, wherein the polypeptide is to be administered daily for 2 to 5 consecutive days preferably for 3 consecutive days.

5. Use according to any one of claims 1 to 4, wherein the young child is aged less than 24 months.

6. Use according to any one of claims 1 to 5, wherein the anti-RSV immunoglobulin single variable domain comprises a CDR1 having the amino acid sequence of SEQ ID NO: 46, a CDR2 having the amino acid sequence of one of SEQ ID NOs: 49-50, and a CDR3 having the amino acid sequence of SEQ ID NO: 61.

7. Use according to claims 6, wherein the polypeptide is SEQ ID NO: 71.

8. Use according to any one of claims 1 to 7, wherein the polypeptide is to be administered as a monotherapy.

9. Use according to any one of claims 1 to 7, wherein at least one additional therapeutic agent is to be administered, preferably a bronchodilator.

10. A nebulizer comprising 0.100-0.400 mL of a 50 mg/mL composition of a polypeptide that binds F-protein of hRSV with a K_D of $5x10^{-10}$ M or less, that neutralizes hRSV with an IC90 of 90 ng/mL or less, and that comprises, consists essentially of, or consists of three anti-hRSV immunoglobulin single variable domains.

11. The nebulizer according to claim 10, wherein at least one anti-RSV immunoglobulin single variable domain comprises a CDR1 having the amino acid sequence of SEQ ID NO: 46, a CDR2 having the amino acid sequence of one of SEQ ID NOs: 49-50, and a CDR3 having the amino acid sequence of SEQ ID NO: 61.

12. The nebulizer according to claim 11, wherein the polypeptide is SEQ ID NO: 71.

13. The nebulizer according to any one of claims 10 to 12, which is a vibrating mesh nebulizer.

14. The nebulizer according to any one of claims 10 to 13, which has a fixed flow of air or oxygen.

15. The nebulizer according to any one of claims 10 to 14, for use in the treatment of RSV infection in a young child, preferably a young child aged less than 24 months.

16. The nebulizer according to any one of claims 10 to 15, wherein the polypeptide is to be administered as a monotherapy.

17. The nebulizer according to any one of claims 10 to 15, wherein at least one additional therapeutic agent is to be administered, preferably a bronchodilator.

18. The nebulizer according to any one of claims 10 to 17 comprising:

(a) an aerosol generator with a vibratable mesh;

(b) a reservoir for a liquid to be nebulised, said reservoir being in fluid connection with the vibratable mesh;

(c) a gas inlet opening;

(d) a face mask, having

- a casing,
- an aerosol inlet opening,
- a patient contacting surface, and
- a one-way exhalation valve or a two-way inhalation/exhalation valve in the casing having an exhalation resistance selected in the range from 0.5 to 5 mbar; and

(e) a flow channel extending from the gas inlet opening to the aerosol inlet opening of the face mask, the flow channel having

- a lateral opening through which the aerosol generator is at least partially inserted into the flow channel,
- a constant flow resistance between the gas inlet opening and the aerosol inlet opening of the face mask at a flow rate of 1 to 20 L/min.